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Background: The diagnostic evaluation of inherited platelet disorders (IPDs) is complicated and time-consuming,
resulting in a relevant number of undiagnosed and incorrectly classified patients. In order to evaluate the spectrum
of IPDs in individuals with clinical suspicion of these disorders, and to provide a diagnostic tool to centers not
having access to specific platelets studies, we established the project “Functional and Molecular Characterization of
Patients with Inherited Platelet Disorders” under the scientific sponsorship of the Spanish Society of Thrombosis and
Haemostasis.
Patients/methods: Subjects were patients from a prospective cohort of individuals referred for clinical suspicion of
IPDs as well as healthy controls. Functional studies included light transmission aggregation, flow cytometry, and when
indicated, Western-blot analysis of platelet glycoproteins, and clot retraction analysis. Genetic analysis was mainly
performed by sequencing of coding regions and proximal regulatory regions of the genes of interest.
Results: Of the 70 cases referred for study, we functionally and molecularly characterized 12 patients with
Glanzmann Thrombasthenia, 8 patients with Bernard Soulier syndrome, and 8 with other forms of IPDs. Twelve novel
mutations were identified among these patients. The systematic study of patients revealed that almost one-third of
patients had been previously misdiagnosed.
Conclusions: Our study provides a global picture of the current limitations and access to the diagnosis of IPDs,
identifies and confirms new genetic variants that cause these disorders, and emphasizes the need of creating
reference centers that can help health care providers in the recognition of these defects.
Keywords: Bernard Soulier syndrome, Glanzmann thrombasthenia, Inherited platelet disorders, Chediak-Higashi
syndrome, Hermansky Pudlak syndrome, ANKRD26, Congenital amegakaryocytic thrombocytopeniaBackground
Inherited platelet disorders (IPDs) constitute a group of
relatively uncommon isolated diseases usually character-
ized by a lifelong mild to moderate bleeding diathesis,
with a true incidence still unknown. Although individual
IPDs are rare and a population based study on the overall
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unless otherwise stated.in aggregate they may be as prevalent as von Willebrand
disease (vWD), the most common inherited bleeding dis-
order [1-3].
A few classic IPDs such as Bernard–Soulier Syndrome
(BSS) and Glanzmann Thrombasthenia (GT) have been
molecularly characterized for over 20 years, while others
such as inherited disorders of signaling pathways down-
stream from membrane receptors are still in many cases
difficult to diagnose since the molecular and genetic
mechanisms are in the vast majority of patients unknown
[4]. Following the suspicion of an IPD, the diagnosis
should be attained by a combination of an appropriateentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ard laboratory studies, including an assortment of platelet
morphologic and functional studies, and ideally, confirma-
tory, targeted-gene analyses [5-8]. However, the identifica-
tion of many platelet disorders has been hampered by the
lack of common international consensus criteria for diag-
nostic algorithms, and also by the limited access to specific
platelets studies and to molecular tests which are usually
performed only by a relatively small number of highly spe-
cialized laboratories [8]. Additionally, it’s been long estab-
lished that platelet functional studies are to be performed
within a limited time after blood collection, although the
feasibility of performing those tests at a more extended
time lapse when evaluating severe platelet defects has rarely
been addressed [9]. Consequently, diagnosed cases are fre-
quently clustered around such centers, while elsewhere
>50% of patients who are likely to be affected remains par-
tially characterized and without a molecular diagnosis
[10,11]. As information develops from the study of IPDs,
more patients will be identified, expanding our understand-
ing about normal platelet biochemistry and physiology, and
our knowledge of the functional network and critical do-
mains of specific platelet elements. These investigations
will provide patients with clearer clinical diagnoses, and
will permit to identify affected family members, as well as
benefit patients from genetic counseling. Moreover, these
studies are essential to distinguish these diseases from ac-
quired platelet disorders to avoid unnecessary and poten-
tially harmful treatments, and to educate patients on when
to seek for specific therapies and about the effect of lifestyle
on hemostasis [12,13]. Although sporadic IPDs from the
Iberian Peninsula have been described, until recently, no
reference laboratory to assist physicians on the diagnosis of
patients with suspected IPDs was available. Therefore, to
respond to such a challenge, and with the aims to (1) evalu-
ate the accuracy of previous diagnoses of IPD by non-
specialized diagnostic laboratories, (2) analyze the feasibility
of performing reliable platelet functional studies within the
24 hours from phlebotomy, under specific conditions, (3)
and to confirm a diagnosis of IPD at a molecular level we
undertook this study. Presented information includes data
from the “Functional and Molecular Characterization of
Patients with Inherited Platelet Disorders” a collabora-
tive project that was undertaken under the scientific sponsor-
ship of the Spanish Society of Thrombosis and Hemostasis.
The main part of this manuscript focuses on describing
our findings from patients diagnosed with two severe
autosomal recessive IPDs affecting the platelet adhesion
and aggregation, BSS and GT respectively [14,15].
Methods
Patient selection and blood drawing
In the course of the last five years, samples from 70 un-
related patients with a clinical suspicion of IPD fromdifferent Spanish and Portuguese hospitals have been an-
alyzed for this study. Venous blood was drawn from
each patient and a parallel healthy control that had not
taken antiplatelet medication for at least 2 weeks, and
samples from both individuals were delivered within 18–
24 hours by express courier at room temperature to Murcia,
Spain, where all further studies were done. Moreover,
fresh blood was taken from a healthy volunteer from our
facility each day that functional studies were performed,
and served as an additional control. Seventeen patients had
their blood drawn at our institution, and in those cases,
blood specimens were only collected from fresh (not par-
allel) controls. Blood samples were collected into com-
mercial 7.5% K3 EDTA tubes (for complete blood count
[CBC], and DNA & RNA isolation), and into buffered
3.2% sodium citrate (for platelet functional studies) using
a 20-gauge needle. Immediately after blood collection, all
tubes were mixed by gentle inversion at least 6 times (and
discarded if there was any evidence of clotting), and sam-
ples were maintained at room temperature (20-25°C) dur-
ing shipping.
All individuals gave informed consent; the sampling
from the children was carried out with the permission of
the parents. Controls, patients, and relatives were fully in-
formed of the aim of this study, which was performed ac-
cording to the declaration of Helsinki, as amended in
Edinburgh in 2000. This study obtained approval from the
Reina Sofia Hospital Ethics Committee.
The bleeding tendency of patients and their relatives
was recorded by the medical doctors using a bleeding
score (BS) questionnaire that recorded the most frequent
and typical symptoms from 0 to 3 [16,17]. The recorded
data were then processed providing a numerical assess-
ment of bleeding severity (Table 1). Considering that
sending samples to a distant laboratory might pose the
problem of missing mild platelet defects, we restricted the
study to patients with significant bleeding history. In the
absence of specific features (see below) we required for a
patient to be considered eligible to be included in this
study, (1) a bleeding score score ≥3 in male subjects, ≥5 in
female subjects, and ≥2 in the pediatric population, and
(2) more than 3 bleeding symptoms in the adult popula-
tion. Exceptions to these inclusion criteria were the 7
patients presenting specific features characteristic of IPDs:
2 patients with hypopigmentation and giant granules in
polymorphonuclear leukocytes characteristic of Chediak-
Higashi syndrome (CHS), 1 patient with oculocutaneous
albinism and nystagmus suggestive of Hermansky-Pudlak
syndrome (HPS), 2 patients with macrothrombocytopenia
and leukocyte inclusion bodies typical of MYH9-related
disorder (MYH9-RD), 1 patient with a hypocellular bone mar-
row exhibiting a near complete absence of megakaryocytes
distinctive of congenital amegakaryocytic thrombocytopenia
(CAMT), and 1 patient with a three-generation family
Table 1 Clinical characteristics and bleeding score of patients included in the study
GT BSS CHS HPS MYH9-RD CAMT THC2 SSD Presumably misdiagnosed Total
n = 13 n = 8 n = 2 n = 1 n = 2 n = 1 n = 1 n = 19 n = 23 n = 70
Sex (F/M) 9/4 6/2 1/1 0/1 1/1 0/1 1/0 13/6 16/7 47/23
Age at clinical suspicion/diagnosis
(median ± SD)
10 ± 10 12 ± 5 5 ± 1 2 30 ± 21 6 12 29 ± 24 13 ± 19 12 ± 19
Age at referral for study
(median ± SD)
32 ± 18 40 ± 7 12 ± 11 28 34 ± 16 21 36 38 ± 21 36 ± 19 35 ± 18
Mean BS 10.5 11.8 0 6 0.5 8 6 8.6 6.1 7.9
% Patients with BS ≥ 2
• Epistaxis 54 100 0 0 0 100 0 21 30 38
• Cutaneous symptoms 58 50 0 0 0 0 0 47 25 38
• Minor wounds 8 13 0 0 0 0 0 26 16 15
• Oral cavity bleeding 46 38 0 0 0 0 0 21 10 22
• Gastrointestinal bleeding 31 33 0 0 0 0 0 26 21 23
• Tooth extraction 33 57 0 100 0 N/A N/A 46 31 38
• Surgery 40 71 0 100 0 100 N/A 73 38 51
• Menorrhagia 100 100 0 N/A 0 N/A 100 67 62 76
• Postpartum hemorrhage 33 75 0 N/A 0 N/A 0 40 33 39
• Hematomas or hemarthrosis 8 0 0 0 0 0 0 11 16 10
The Table reflects the clinical characteristics of patients that were confirmed to have a final diagnosis consistent or not (in such case considered “presumably
misdiagnosed”) with the previously suspected IPD, the total bleeding score, and the percentage of patients with clinical significant bleeding (grades 2 or 3) for
each symptom. For each symptom the grades of bleeding severity ranged from 0 (absence of symptoms) to 3. Grade 1 was given when a patient reported the
presence of bleeding, grade 2 if the symptom required evaluation by a physician but no active intervention, and grade 3 if there was some type of intervention.
The final bleeding score was generated by summing the severity of all bleeding symptoms reported by the patient [16,17].
Abbreviations: BS Bleeding score, BSS Bernard Soulier syndrome, CAMT congenital amegakaryocytic thrombocytopenia, CHS Chediak-Higashi syndrome, F Female,
GT Glanzmann Thrombasthenia, HPS Hermansky-Pudlak syndrome, M Male, MYH9-RD MYH9 related disorder, N/A not applicable, SSD platelet secretion and signal
transduction defects, THC2 thrombocytopenia 2.
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normal mean platelet volume (MPV), suggestive of defects
in megakaryocyte maturation.
Before any additional testing, it was mandatory to have
results from the following tests: basic biochemical tests
including renal and liver function, prothrombin time, acti-
vated partial thromboplastin time, CBC, MPV, and mor-
phological examination of a blood smear. In patients not
exhibiting thrombocytopenia, additionally Clauss fibrino-
gen, factor VIII: C activity, von Willebrand factor (vWF)
antigen, and ristocetin cofactor activity assay were studied.
Patients were excluded from further laboratory testing
after a diagnosis of acquired defects or vWD. Subject diag-
noses were based on the opinion of the referring phys-
ician, and the BS questionnaire, and medical records were
examined by two physicians from our facility who also
reviewed laboratory data. Definitive diagnoses of IPDs
were compared to the clinical suspicion by the referring
physician, and sub-classified as previously being accurately
diagnosed or as presumably misdiagnosed, based on
platelet functional studies as well as on molecular find-
ings. Initial evaluation at our institution also included
platelet aggregation, glycoprotein expression, and analysis
of activation markers by flow cytometry, and if indicated,specialized tests were performed, including clot retraction,
and molecular studies.
Platelet functional studies
Platelet rich plasma (PRP) was prepared by centrifugation
of citrated whole blood at 150 × g for 10 min and the top
two-thirds removed by careful pipetting into a separate
tube. Platelet poor plasma (PPP) was prepared by a further
centrifugation step of the same tube at 1000 × g for 20 min.
PRP from citrated blood samples that appeared macro-
thrombocytopenic on blood smears were prepared by
means of tilting the tube to an angle of 45° for 1-2 h [18].
Light transmission aggregometry (LTA) was performed
as described [19] using undiluted PRP when the platelet
concentration of patient’s and control’s PRP samples
were in the range of 200 and 600 × 109 L−1 [20]. When
the patient’s PRP count was below 150 × 109 L−1, we di-
luted the control’s sample with autologous PPP, in order
to have similar optical densities (±10%). Time course
changes in the maximal percentage of light transmis-
sion of PRP over baseline (PPP) were recorded for
300s using an Aggrecorder II aggregometer (Menarini
Diagnostics, Florence, Italy). Agonists used for LTA included:
2 μg mL−1 collagen, 10 μM ADP; 1.6 mM arachidonic acid,
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Activating Peptide (TRAP). In patients with clinical suspi-
cion of GT, responses to 100 nM phorbol myristate acet-
ate (PMA) were also analyzed; in those with suspicion of
BSS, only aggregatory responses to ristocetin and TRAP
were assessed. Some subjects were not tested with all ago-
nists. LTA samples were preincubated (37°C, 3 min), and
all tracings were inspected by the same person (JR), who
provided an overall interpretative comment. Platelet ag-
gregation was considered abnormal if it was reversible, or
if the maximum amplitude was <40% of the paired parallel
control drawn the same day and shipped under similar
conditions than samples from each patient. If the samples
from such paired control from the referring center exhib-
ited considerable weaker responses to 25 μM TRAP than
those of the fresh control (<30%), the tubes were dis-
carded for functional analysis, and further samples were
requested for analysis.
For flow cytometry, citrated whole blood diluted 1:10 in
saline buffer was assessed for expression of major platelet
membrane glycoproteins (GP) that support platelet adhe-
sion and aggregation (GPIa, GPIbα, αIIb, β3) through a dir-
ect standard flow cytometry technique with appropriate
labelled monoclonal antibodies in a FACScalibur platform
(Becton Dickinson, San Jose, CA). PRP was used to study
platelet activation markers (P-selectin, granulophysin
[stimulated with 25 μM TRAP]), and activated αIIbβ3 com-
plex (unstimulated and activated with 100 nM PMA or 10
μM ADP). Monoclonal antibodies (Becton Dickinson)
used were FITC*CD49b (GPIa), FITC*CD42b (GPIbα),
PE*CD41a (αIIb), FITC*CD61 (β3), FITC*PAC-1 (activa-
tion-specific antiαIIbβ3 antibody), PE*CD62 (P-selectin),
and PE*CD63 (granulophysin). For each sample run, data
acquisition of 10,000 events was gated on forward and
side-angle light scatter with gains adjusted to include the
platelet population. Then, the fluorescence of stained plate-
lets was analysed (CellQuest software, Becton Dickinson)
to obtain both the percentage of positively stained cells
and the mean fluorescence intensity (MFI).
For patients with the clinical suspicion of GT, we add-
itionally tested the in vitro haemostatic response through
the “clot retraction assay”. PRP samples were diluted in
homologous PPP to final platelet counts of 300 × 109L−1
and incubated in glass tubes for 5 minutes at 37°C. Clot
formation was induced by calcium chloride (8 mM L−1
final concentration), and samples were photographed and
weighed after 1 hour of incubation at 37°C [21].
Samples from patients showing reduced/absent αIIbβ3,
or GPIb/IX expression underwent Western blot ana-
lysis of platelet glycoproteins, by standard procedures
using specific antibodies recognizing αIIb (132.1, Blood
Research Institute, Milwaukee, WI), β3 (AP3, Blood
Research Institute, Milwaukee, WI), and GP Ibα (LJ-Ib10,
La Jolla, CA).Molecular characterization
DNA and RNA were isolated from each patient by stand-
ard procedures, and stored frozen until use. Molecular
analysis of candidate genes was done in patients with a la-
boratory diagnosis of GT or BSS (see below), and also in
patients with clinical and laboratory suspicion of MYH9-
RD, CHS, HPS, Platelet von Willebrand disease (PvWD),
CAMT, and thrombocytopenia 2 (THC2).
To detect mutations in ITGA2B (ENSG00000005961)
or ITGB3 (ENSG00000259207), total RNA from peripheral
blood was used for cDNA synthesis using the Superscript
First Strand Synthesis System for RT-PCR (Invitrogen,
Paisley, UK), following the manufacturer’s protocol.
Using specific oligonucleotides and conditions (primer
sequences and conditions are available upon request) we
amplified and sequenced ITGA2B and ITGB3 by Sanger’s
approach. Every mutation found in cDNA was confirmed
on DNA samples.
The GP1BA (ENSG00000185245), GP1BB (ENSG0000
0203618) and GP9 (ENSG00000169704) genes were screened
for mutations using genomic DNA. Genomic fragments
were analysed by polymerase chain reaction (PCR) using
primers designed specifically to amplify the coding re-
gions (primer sequences and conditions are also avail-
able upon request). PCR products were sequenced in
the ABI 3130xl genetic analyser (Applied Biosystems,
Carlsbad, CA).
Patients with the clinical suspicion of other IPDs were
studied and screened for mutations in the specific candi-
date gene. Thus, all exons and intron-boundaries of
HPS1 (ENSG00000107521) were sequenced by Sanger’s
method in two patients with the clinical suspicion of
HPS; in one of these patients HPS4 (ENSG00000100099)
was additionally sequenced. RNA from patients with
the suspicion of CHS and MYH9-RD was extracted,
and cDNA was amplified and sequenced seeking muta-
tions in LYST/CHS1 (ENSG00000143669) and MYH9
(ENSG00000100345), respectively. When the clinical
suspicion was PvWD, CAMT, or THC2, the molecu-
lar approach contemplated the direct analysis of the
most affected DNA regions in these disorders: exon 2
of GP1BA in PvWD [22], the first 3 exons of MPL
(ENSG00000117400) gene in CAMT [23], and the 5′
UTR region of ANKRD26 (ENSG00000107890) in
THC2 [24]. In one patient with clinical suspicion of
BSS not confirmed by functional and molecular studies,
exome sequencing was performed (Agilent SureSelect
Capture v4 + UTRs and Genome Analyzer IIx plat-
form, Agilent Technologies, Santa Clara, CA). Using
RUbioSeq software [25] sequencing data were aligned
to the human reference genome (GRCh37) and exome
variant analysis and functional prediction were per-
formed with the default parameters for somatic vari-
ation analysis.
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Of the 70 patients enrolled in this study, molecular
characterization of GT was achieved in 12 patients, while
the causative mutation/s was recognized in 8 cases of
BSS, in 2 with CHS, 1 with HPS, 3 with MYH9-RD, 1 with
CAMT, and 1 withTHC2 (10 men and 18 women) (Table 2).
In these patients, the median age at first suspicion of
IPD was 10 years; the median age at which an IPD
was molecularly confirmed was 34 years. Overall, 12
novel mutations have been identified in this study. In
about two-third of the cases that had been referred with a
clinical suspicion/diagnosis of IPD, our functional and
molecular approach confirmed a definitive diagnosis of
platelet disorder. However, the median age at which IPD
was confirmed in these 47 patients was 35 years, indicat-
ing that there was a significant delay (24 years) from the
time an IPD was first suspected to the time confirmatory
evaluation was requested. In about one-third of the cases
(n = 27) that had been suspected of having IPD during a
median period of 23 years (the median age when IPD
was suspected and when specific laboratory evaluation
was performed was 13 and 36 years, respectively) our
approach could not confirm such diagnosis, and were
therefore categorized as presumably misdiagnosed. Table 2
reflects the observed misdiagnosis rate according to spe-
cific platelet disorders that had been clinically suspected.
Glanzmann thrombasthenia
Thirteen patients were diagnosed with GT (4 men and 9
women, with a median age of 32 years) (Tables 1 and 3).
The disorder was readily identifiable in the presence of a
normal platelet number (109-280 × 109 platelet L−1) and
size, and by platelet function testing, consisting in severelyTable 2 Molecular and functional characterization of patients
Diagnostic suspicion at referral n Confirmed IPDs
Phenotype/Func
Signaling and/or secretion disorder 25 19 (76%)
Glanzmann thrombasthenia 20 13 (65%)
Bernard-Soulier syndrome 13 8 (61.5%)
Chediak-Higashi syndrome 2 2 (100%)
Hemansky-Pudlak syndrome 2 1 (50%)
MYH9-RD 4 2 (50%)
Platelet von Willebrand disease 2 0
Congenital Amegakaryocytic Thrombocytopenia 1 1
Thrombocytopenia 2 1 1
All IPDs Referred 70 47 (67.1%)
Abbreviation: IPDs inherited platelet disorders, MYH9-RD MYH9 related disorder, MU
*One of the patients referred with a clinical suspicion of BSS was diagnosed as havimpaired aggregation in response to all physiological ago-
nists, and also to PMA (Table 4). Ristocetin-induced plate-
let agglutination (RIPA) was normal or reduced to some
extent (74 ± 25%), and GPIbα and GPIX expression was
normal in all patients, while clot retraction was consist-
ently abnormal. On flow cytometry 8 patients (GT-2,
GT-4, GT-5, GT-8, GT-9, GT-10, GT-12 and GT-13)
were diagnosed as type I GT (<5% of αIIbβ3 expression), 4
(GT-1, GT-3, GT-6 and GT-7) as type II GT (αIIbβ3 ex-
pression between 5% and 20%), while 1 patient (GT-11)
was classified as variant GT (50% expression but recep-
tor being not functional according to LTA and clot
retraction). All patients exhibited no binding of PAC-1
activation-specific anti- αIIbβ3 antibody upon stimulation
with ADP or TRAP. In platelet lysates from type II pa-
tients, faint but detectable αIIbβ3 bands of the expected ap-
parent molecular weight were seen, while platelets from
the patient with variant GT showed reduced (50% of nor-
mal) levels of these proteins (data not shown).
Patients presented with a variable bleeding diathesis as
measured by the BS (mean BS of 10.5, Table 1). Considering
grades 2 and 3 as clinical significant bleeding, most of the
patients had gross blood loss due to epistaxis (54%), cutane-
ous bleeding (58%) and menorrhagia (100% of women),
while other common symptoms (oral cavity, gastrointes-
tinal, following dental extraction or mild injuries, postpar-
tum, or hematomas) were in general milder.
In order to determine the causative mutations, ITGB3
and ITG2B genes were analyzed, allowing us to identify
mutations in all patients but one (Table 3). Overall, 11
mutations were found in ITGA2B and 5 in ITGB3. Of
the 16 alterations, 8 were novel mutations, including 2
nonsense mutations (leading to premature stop codonswith IPDs
(n = 47) Presumably misdiagnosed (n = 23)
tional Molecular diagnosis Cases Presumptive diagnosis
0 6 (24%) No platelet defect
12 7 (35%) Signaling and/or secretion
disorders
8 5 (38.5%) MUO (n = 4)
MYH9-RD (n = 1)*
2 0 -
1 1 (50%) No molecular confirmation
of disease
3* 2 (50%) MUO
- 2 (100%) No definitive diagnosis
1 0 -
1 0 -
28 (40.0%) 23 (32.9%)
O macrothrombocytopenia of unknown origin.
ing MYH9-related disorder.
Table 3 Molecular diagnosis of patients with Glanzmann Thrombasthenia
Patients with molecular diagnosis Gene Inheritance Mutation Reference
GT-1 GT II ITGB3 Compound Heterozygous p.Met124Val [30]
c.774-775delTG new
GT-2 GT I ITGA2B Compound Heterozygous p.Leu183Pro [26]
c.2473_2481delinsTCACCTGGTC new
GT-3 GT II ITGA2B Homozygous p.Cys674Arg [27]
GT-4 GT I ITGB3 Homozygous p.Tyr190Cys new
GT-5 GT I ITGA2B Compound Heterozygous p.Glu507stop new
c. 2637delC new
GT-6 GT II ITGA2B Compound Heterozygous p.Val951Met [31]
p.Ala958Thr [31]
p.Glu507stop new
GT-7 GT II ITGB3 Homozygous p.Met118Arg [32]
GT-8 GT I ITGA2B Homozygous c.2965delG new
GT-9 GT I ITGA2B Homozygous c.692insT [28]
GT-10 GT I ITGA2B Homozygous c.1599delAT new
GT-11 GT Variant ITGB3 Compound Heterozygous p.Tyr190Cys new
p.Leu196Pro [29]
GT-12 GT I ITGB3 No mutation found - -
GT-13 GT I ITGA2B Homozygous p.Trp51Stop new
Abbreviation: BS bleeding score, GT Glanzmann Thrombasthenia.
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ITGA2B (c.2637delC, c.2965delG, and c.2473_2481delins
TCACCTGGTC) and one in ITGB3 (c.774-775delTG),
one mutation affecting a splice site c.1599delAT in
ITGA2B, and one missense p.Tyr190Cys in ITGB3; the
other 8 mutations were already described in the literature
[26-32]. As GT is an autosomal recessive disease, patients
are mostly compound heterozygotes for ITGA2B or
ITGB3 mutations in the absence of consanguinity. Homo-
zygous mutations were found in three patients (GT-3,
GT-9, and GT-13) from non-consanguineous families -to
the best of our knowledge, and in all patients with consan-
guineous family history. Despite complete sequencing, noTable 4 Maximal aggregation (%) of patients and controls
Platelet count
(×109 L−1)
TRAP
(25 μM)
ADP
(10 μM)
GT (n = 13) 171.7 ± 42.5 18.3 ± 4.5 3.0 ± 5.2
BSS (n = 8) * 49.4 ± 21.1 -
SSD (n = 19) 197.6 ± 77.8 80.7 ± 11.2 53.9 ± 27.0
Parallel controls (n = 31)‡ 216.3 ± 48.9 83.7 ± 12.7 78.1 ± 16.8
Fresh controls (n = 40) 210.6 ± 32.4 90.7 ± 7.8 86.3 ± 7.3
The Table reflects aggregation responses of patients diagnosed with GT, BSS, SSD, p
time of analysis. All values are mean ± standard deviation. *Always <20 × 109 platel
the paired patient’s aggregation profile was consistent with GT. ‡Blood samples fro
defects were drawn at our institution, and in those cases blood specimens were on
Abbreviations: ADP Adenosine diphosphate, BSS Bernard Soulier Syndrome, GT Glan
phorbol myristate acetate, SSD platelet secretion and signal transduction defects.potential pathological mutations were located in either
gene of patient GT-12, who exhibited a family history of
consanguineous union, and presented no detectable levels
of ITGB3 mRNA by qRT-PCR (data not shown).
Segregation analysis confirmed the presence of hetero-
zygous mutations in all available carriers (parents) ex-
cept patient GT-6. Interestingly, patient GT-6 exhibited
a triple heterozygosity in the integrin αIIb subunit, as a
result of a nonsense mutation (p.Glu507Stop) of paternal
origin, and two de novo missense changes, p.Val951Met,
and p.Ala958Thr, that had been previously described in
another GT patient [31]. Noteworthy, the already re-
ported missense mutations- found together with a spliceRistocetin
(1.25 mg mL−1)
Arachidonic acid
(1.6 mM)
Collagen
(2 μg mL−1)
PMA
(100 nM)
74.1 ± 24.7 9.8 ± 5.0 8.2 ± 9.6 8.8 ± 4.4
4.4 ± 2.5 - - -
84.6 ± 17.8 72.1 ± 25.8 45.7 ± 36.4 -
80.3 ± 19.4 77.4 ± 23.3 78.0 ± 18.6 45.2 ± 22.3#
90.9 ± 7.1 88.8 ± 6.6 88.1 ± 6.8 58.5 ± 20.4#
arallel controls (drawn simultaneously to patients), and controls drawn at the
et L−1; #Aggregation responses to PMA were assessed in controls only when
m nine patients diagnosed with secretion and signal transduction platelet
ly collected from fresh (not parallel) controls.
zmann Thrombasthenia, TRAP thrombin receptor activating peptide, PMA
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mother- were paternal in origin and cosegregated in the
same allele across three generations [31]. In our patient,
however, throughout investigation of other family mem-
bers (father, mother, brother) did not detect the two mis-
sense mutations in any of the individuals, and DNA
profiles generated from blood from the patient and par-
ents revealed double paternal/maternal contribution at
different loci in the propositus, confirming the maternal
and parental relationship.
To define the structural impact of the new missense
mutation p.Tyr190Cys, identified in two of our patients
(patients GT-4 and GT-11), the role of the amino acid
substitutions in β3 was analyzed in silico. The three di-
mensional diagram of the Cys190 suggested a disruption
of the hydrogen bond created in between Tyr190 and
Tyr115. This change would also generate new hydrogen
bond with Gly189, predicting a destabilizing effect on
the fold (data not shown).
Bernard Soulier syndrome
This syndrome was diagnosed in eight individuals (2 men
and 6 women with a median age of 40 years) (Tables 1
and 5). In these patients, platelet count was consistently
less than 20 × 109 L−1 by commercial cell counters, with
persistent findings of giant platelets in the peripheral
blood smear. Patients had slightly diminished aggregation
responses to TRAP compared to their parallel controls,
but RIPA was absent or severely defective in all patients
(Table 4). Flow cytometry revealed that the GPIbα and
GPIX expression was severely reduced (<10% compared
to controls). MFI of other platelet GPs were normal or
increased due to the increased size of the cells. Fur-
ther studies using Western-blot analysis revealed an
absent or severely reduced GPIbα band in all patients
(data not shown).
More than half of the patients (BSS-2, BSS-5, BSS-6,
BSS-7 and BSS-8) had been splenectomized without hav-
ing any benefit, as they had been previously misdiagnosedTable 5 Molecular diagnosis of Bernard Soulier syndrome pat
Patients with molecular diagnosis Gene Inher
BSS-1 GP9 Homo
BSS-2 GP1BA Homo
BSS-3 GP1BA Possib
BSS-4 GP9 Homo
BSS-5 GP9 Homo
BSS-6 GP9 Homo
BSS-7 GP9 Homo
BSS-8 GP1BB Homo
Abbreviations: BS bleeding score, BSS Bernard Soulier Syndrome.with primary immune thrombocytopenia (ITP). The se-
verity grade, measured by BS for epistaxis and menorrha-
gia was 2 & 3 in 100% of patients. Other less prevalent
locations of moderate-severe blood loss were cutaneous
bleeding (50% of patients), and following procedures of
dental extraction, surgery, or delivery (57%, 71%, and 75%
of patients, respectively). Mild bleeding symptoms were
reported at other sites (bleeding from minor wounds, oral
cavity, or gastrointestinal tract). The overall BS in BSS pa-
tients was 11.8 (Table 1).
Disease-causing homozygous mutations were found in
7 out of 8 patients -five lacking a history of known family
consanguinity-, while in the remaining patient a mutation
was identified in only one allele of GP1BA (Table 5). Six
mutations were detected (3 in GP9, 2 in GP1BA, and 1
in GP1BB); half of them had been already described in
the literature [33-36] and the other 3 were new (one in
GP1BA, one in GP1BB, and one in GP9). Of these novel
mutations, 2 of them were missense, Trp71Arg in exon 3
of GP9, and Pro64Ser in exon 2 of GP1BB. Of note, the p.
Gln90_Leu92del mutation, which leads to the loss of 3
amino acids in one of the leucine rich-repeat sequences of
GPIbα, was found in heterozygosis in one patient. We did
not consider this patient as having the milder monoallelic
autosomal dominant form of BSS [37-40], due to the ab-
sent GPIbα and GPIX expression by flow cytometry, and
the low platelet count (<20 × 109 L−1). Additionally, this
variant was also identified in the patient’s mother, with no
BSS phenotype at all. Hence, there might be other un-
known genetic defects or different molecular mechanisms,
such as transcription factors or post translational defects
[41] that could lead to BSS phenotype in this patient. It is
worth mentioning that the variant p.Phe55Ser, previously
described in a patient from the Netherlands [35] was iden-
tified in 3 unrelated patients from the central region of
Portugal, suggesting that this mutation could have an an-
cient origin in that geographical area.
To predict the effects of the 2 novel missense muta-
tions, we performed in silico analysis of the new variants.ients
itance Mutation Reference
zygous p.Trp71Arg new
zygous p.Cys209Ser [34]
ly Heterozygous p.Gln90_Leu92del new
- -
zygous p.Asn45Ser [33,36]
zygous p.Phe55Ser [35]
zygous p.Phe55Ser [35]
zygous p.Phe55Ser [35]
zygous p.Pro90Ser new
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a change in the isoelectric point that could affect the
interaction with GPIbβ, potentially influencing the correct
folding and expression of the receptor on the platelet
membrane. As for the p.Pro64Ser in GPIbβ, in silico stud-
ies did not show any relevant alteration of the protein
structure but mutation analysis using different bioinfor-
matics tools (Poly-Phen2, Mutation Taster) characterized
this change as a damaging variant for the protein and a
disease causing mutation (data not shown).
Other IPDs
The molecular characterization of patients with the clin-
ical suspicion of other IPDs resulted in the identification
of 8 molecular alterations, 3 recently reported by us
[42,43]. We did not confirm any of the 2 PvWD suspi-
cions. Two homozygous mutations in LYST corroborated
the diagnosis of CHS in 2 patients: p.Cys258Arg and p.
Gly3725Arg [42], while HPS was confirmed in one pa-
tient (p.Glu204Stop) [43]. Three monoallelic mutations,
already described in the literature [44,45], were detected in
MYH9 patients: 2 patients had been referred to our cen-
ter with the clinical suspicion of MYH9 (p.Arg1165Cys,
p.Glu1841Lys), while the remaining individual had been
clinically misdiagnosed as having BSS. In this patient
with macrothrombocytopenia and no evident neutrophil
inclusions on conventional May-Grünwald-Giemsa-stained
blood, whole exome sequencing detected the p.Asp1424Glu
variant in MYH9 [45]. Molecular diagnosis of CAMT
was attained in one patient by the identification of the
homozygous p.Arg102Cys [23] mutation in MPL. THC2
was diagnosed in an additional patient with a clear family
history of autosomal dominant thrombocytopenia with
normal MPV, as the monoallelic c.-128G >A variant [24]Table 6 Molecular diagnosis of other inherited platelet disord
Patients with molecular diagnosis Gene
Chediak-Higashi Syndrome (CHS)
CHS-1 LYST/C
CHS-2 LYST/C
Hemansky-Pudlak Syndrome (HPS)
HPS-1 HPS1
MYH9 related disorders (MYH9-RD)
MYH9-RD-1 MYH9
MYH9-RD-2 MYH9
MYH9-RD-3 MYH9
Congenital Amegakaryocytic Thrombocytopenia (CAMT)
CAMT-1 MPL
Thrombocytopenia 2 (THC2)
THC2-1 ANKRDin the 5′UTR region of the ANKRD26 gene was detected.
(Table 6). Patients presenting with non-syndromic nor-
mal or mildly reduced platelet counts, decreased aggrega-
tion responses to collagen, and/or ADP, and impaired
externalization of platelet activation markers in response
to TRAP were lumped in the remarkably heterogeneous
group of platelet secretion and signal transduction defects,
and no further analysis were performed.
Discussion
In this study, we evaluated the largest cohort of BSS and
GT patients in the Iberian Peninsula, following the aim of
the project “Functional and Molecular Characterization of
Patients with Inherited Platelet Disorders”. By reviewing
the medical records, BS questionnaire, performing func-
tional studies, and when possible, identifying the under-
lying genetic abnormality, amongst the 70 patients referred
to us for a diagnostic confirmation of IPD, we concluded
that 32.9% had been previously misdiagnosed, while 40%
achieved a diagnosis at a molecular level (Table 1).
IPDs are one of the most complex, poorly standardized
and time consuming disorders to diagnose. A recent
worldwide survey [46] confirms results from previous
ones [47,48] showing large variations between laborator-
ies in platelet function testing practice, and clearly dem-
onstrates that the required diagnostic technologies are
not always readily available to many facilities, and refer-
ral to specialized centers may be necessary for definitive
diagnosis [49]. Even though sending samples to a distant
laboratory might pose the problem of missing mild plate-
let defects, due to the time lag between blood extractions
and testing, differences in platelet functional responses to
strong agonists between patients and paired controls
allowed us not only to functionally identify GT and BSSers
Inheritance Mutation Reference
HS1 Homozygous p.Gly3725Arg [42]
HS1 Homozygous p.Cys258Arg [42]
Homozygous p.Glu204Stop [43]
Heterozygous p.Arg1165Cys [44]
Heterozygous p.Glu1841Lys [44]
Heterozygous p.Asp1424Glu [45]
Homozygous p.Arg102Cys [23]
26 Heterozygous c.-128G > A [24]
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heterogeneous category of defects in platelet secretion and
signal transduction.
In that sense, we restricted the study to patients with
significant bleeding history. The selection of candidate
patients justifies the differences in the prevalence of con-
firmed IPD between our study and the previous recent
worldwide survey [46], with a higher percentage of pa-
tients with GT (28.8% vs. 9.8%, respectively), with BSS
(17.7% vs. 4.2%, respectively), and the percentage of pa-
tients that achieve a diagnosis at a molecular level (40%
vs. 8.7, respectively). A reflection of the need to improve
the recognition of IPDs and the absence of referral centers
is that 93% of the patients investigated at our institution
were adults, and although IPD was suspected during
childhood (median age of 12 years), laboratory confirm-
ation of the disorder was not performed until a median of
23 years later. Additionally, even in GT and BSS, defects
in which the diagnosis is rather straightforward, even for
non-specialized laboratories, the percentage of patients
that had been misdiagnosed was high. The long delay in
reaching a definite diagnosis was not without conse-
quences, since 8 subjects underwent undue splenectomy
before our observation (2 with MYH9-related disease, 5
with BSS, 1 with CAMT).
The analysis of the 13 GT patients showed a consist-
ent and homogeneous functional profile and bleeding
complications leading to significant morbidity. Most pa-
tients had a type I phenotype, in accordance with previous
reports [50,51]. The molecular characterization of patients
revealed 16 mutations (half of them not reported previ-
ously) along both genes encoding for the αIIbβ3 receptor:
11 mutations were located in the ITGA2B gene within 8
patients (3 of them were compound heterozygous) and 5
in the ITGB3 in 4 more patients. According to a regularly
updated database (http://sinaicentral.mssm.edu/intranet/
research/glanzmann), and to what has been previously
stated [15], we observed more mutations affecting
ITGA2B possibly because, although a smaller gene than
ITGB3, it has 30 exons (and double number of splice sites)
compared to 15 in ITGB3. In patient GT-12, who has un-
equivocally been diagnosed by functional studies as GT,
no mutations were detected. It is known that no single
screening technique warrants detection of all causative
mutations; previous reports have identified mutations
in 80% of GT patients, by using different techniques,
such as denaturing gradient gel electrophoresis [52],
or by conformation sensitive gel electrophoresis [51].
This suggests that defects in regulatory elements that
adversely affect the transcription of the ITGA2B and
ITGB3 genes or abnormalities in mechanisms that are
responsible for post-translational modifications and traf-
ficking of integrin subunits may also potentially account
for some cases of GT.The detected mutations were analyzed for penetrance
into the individual family members; heterozygous muta-
tions were seen in all of the available samples from the
parents of GT, except in one case. Of note, patient GT-6
exhibited two de novo missense variants in the αIIb sub-
unit, together with a nonsense mutation of parental origin.
Such missense mutations have been previously described
in a patient also with triple heterozygosity in the αIIb gene
[31], indicating that both missense mutations, 8 aminoa-
cids from each other, occur non-randomly but that these
variants are tightly linked. At this moment, the causative
molecule or defect in the repair mechanism responsible
for these de novo mutations are not known. While one of
the missense variants (p.Ala958Thr) was considered to be
a polymorphism in the previous report [31], using exome
databases (Exome Variant Server, NHLBI GO Exome
Sequencing Project (ESP), Seattle, WA (URL: http://evs.
gs.washington.edu/EVS/)), this change was identified as a
mutation (allele frequency < 0.01). Further studies are
needed to clarify the linkage disequilibrium between both
mutations in exon 29 of ITGA2B.
BSS was diagnosed in 8 individuals presenting with
macrothrombocytopenia, decreased/absent levels of GPIbα
and GPIX, and a bleeding tendency with variable severity
among individuals. Similar to GT, all menstruating women
had severe menorrhagia (grades 2 & 3), a finding that
might justify the predominance of females (n = 15) over
males (n = 6) in these two disorders (47 vs 23 considering
the whole cohort), and suggesting that men with GT, BSS,
or IPDs in general, are being underdiagnosed. All cases
but one (patient BSS-3) were homozygous for the same
mutated allele inherited from parents, inferring that these
patients shared a common ancestor (5 out of 8 did not
refer a history of known family consanguinity). This is of
particular relevance in the case of the variant p.Phe55Ser
in GPIX, identified in 3 apparently unrelated patients from
central Portugal.
It has been previously shown that missense mutations hit
GPIbβ and GPIX more frequently than GPIbα, suggesting
that folding and stability of these glycoproteins are more
sensitive to aminoacid substitution than GPIbα [53]. Ac-
cordingly, of the 3 new mutations identified in our study,
the 2 novel missense variants, p.Trp71Arg, and p.Pro64Ser
affected GPIX, and GPIbβ, respectively. Structural model-
ing of these variants predicted deleterious effects.
Until 2011, original studies reported one or two pa-
tients with BSS, with the largest case series including 13
cases [41]. More recently, the BSS Consortium, consti-
tuted of research groups from 15 countries worldwide,
has helped establish the most comprehensive database of
BSS, and data from the 112 different variants characterized
so far have been deposited in the Leiden Open Variation
Database (LOVD) at http://www.lovd.nl/GP1BA, http://
www.lovd.nl/GP1BB, and http://www.lovd.nl/GP9 for the
Sánchez-Guiu et al. Orphanet Journal of Rare Diseases  (2014) 9:213 Page 10 of 12GP1BA, GP1BB, and GP9 genes, respectively [53]. Such
database would be enriched, with the inclusion of the 3
novel mutations identified here.
As for other IPDs, it is known that the molecular diag-
nosis of HPS may not be that simple. Mutations in 9 genes
(HPS1, AP3B1, HPS3, HPS4, HPS5, HPS6, DTNBP1,
BLOC1S3, and BLOC1S6) can cause HPS in humans. By
adopting a classical approach to reach a molecular diagno-
sis in the 2 patients with clinical suspicion of HPS, we se-
lected HPS1 as the first candidate gene to be responsible
for the disease, since it is the one most frequently affected
[54]. We identified a homozygous p.Glu204Stop mutation
in exon 7 of this gene in one of the patients [43]. In the
second patient, further sequencing of HPS4 revealed no
variations; we did not sequence the rest of less frequently
affected genes. Two additional patients presented with
syndromic forms, suggestive of CHS, and a definitive diag-
nosis was made based on molecular findings [42]. One in-
dividual who had been previously misdiagnosed as having
ITP and treated with steroids and splenectomized, exhib-
ited a bone marrow aspirate and biopsy showing de-
creased cellularity and megakaryocyte counts, with 24% of
the metaphases revealing monosomy 7. With the clinical
suspicion of CAMT, sequencing of the MPL gene detected
a homozygous point mutation, p.Arg102Cys previously
described [23]; with a diagnosis of CAMT the patient
underwent a matched unrelated bone marrow trans-
plant. A woman with non-syndromic autosomal-dominant
thrombocytopenia was categorized as having a THC2, due
to the presence of a heterozygous c.-128 G > A ANKRD26
mutation. One patient, who was initially thought by the
referring physician to be affected by BSS, was not con-
firmed by functional studies as having such disease (nor-
mal expression of GPIbα and GPIX, as well as platelet
agglutination induced by ristocetin). In this patient, in
whom MYH9-related disease was not suspected due
to (1) no evident neutrophil inclusions on conventional
May-Grünwald-Giemsa-stained blood, (2) no family history
of macrothrombocytopenia, and (3) no extra-hematological
manifestations, the use of exome sequencing, led us
to identify a monoallelic mutation in the MYH9 gene
(p.Asp1424Glu). This observation supports the possi-
bility that exome sequencing could be used as a diagnostic
tool in the future, to help identify genetic defects in pa-
tients who do not fall into known categories of IPDs, and
to have a deeper knowledge of the molecular and genetic
mechanisms underlying functional defects of patients cur-
rently categorized as having signaling and/or secretion
disorders.
Conclusion
This project highlights the urgent need to significantly
improve the diagnosis of IPDs at the level of the platelet
pathway and by molecular analysis, considering the highpercentage of patients that are still being misdiagnosed,
and those in whom, the molecular mechanisms causing
these defects are still unknown. The requirement of highly
specialized tests represents a particular problem in certain
institutions or areas, and collaborative international efforts
should facilitate advances in patient diagnosis and care.
Consensus standardized criteria for the diagnosis of these
disorders are expected to overcome the present hetero-
geneity between facilities, and the creation of reference
centers should be considered to help health care providers
in the diagnosis of these disorders.
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